| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Endocrinology, Metabolism, and Diabetes, Department of Internal Medicine, University of Utah, Salt Lake City, Utah 84132
Correspondence: Address all correspondence and requests for reprints to: Scott A. Summers, Division of Endocrinology, Metabolism, and Diabetes, Department of Internal Medicine, University of Utah, Salt Lake City, Utah 84132. E-mail: Scott.Summers{at}hsc.utah.edu
Obesity and dyslipidemia are risk factors for metabolic disorders including diabetes and cardiovascular disease. Sphingolipids such as ceramide and glucosylceramides, while being a relatively minor component of the lipid milieu in most tissues, may be among the most pathogenic lipids in the onset of the sequelae associated with excess adiposity. Circulating factors associated with obesity (e.g., saturated fatty acids, inflammatory cytokines) selectively induce enzymes that promote sphingolipid synthesis, and lipidomic profiling reveals relationships between tissue sphingolipid levels and certain metabolic diseases. Moreover, studies in cultured cells and isolated tissues implicate sphingolipids in certain cellular events associated with diabetes and cardiovascular disease, including insulin resistance, pancreatic β-cell failure, cardiomyopathy, and vascular dysfunction. However, definitive evidence that sphingolipids contribute to insulin resistance, diabetes, and atherosclerosis has come only recently, as researchers have found that pharmacological inhibition or genetic ablation of enzymes controlling sphingolipid synthesis in rodents ameliorates each of these conditions. Herein we will review the role of ceramide and other sphingolipid metabolites in insulin resistance, β-cell failure, cardiomyopathy, and vascular dysfunction, focusing on these in vivo studies that identify enzymes controlling sphingolipid metabolism as therapeutic targets for combating metabolic disease.
This article has been cited by other articles:
 |
|
 |
|
  J. R. Bain, R. D. Stevens, B. R. Wenner, O. Ilkayeva, D. M. Muoio, and C. B. Newgard Metabolomics Applied to Diabetes Research: Moving From Information to Knowledge Diabetes, November 1, 2009; 58(11): 2429 - 2443. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Hu, J. Bielawski, F. Samad, A. H. Merrill Jr., and L. A. Cowart Palmitate increases sphingosine-1-phosphate in C2C12 myotubes via upregulation of sphingosine kinase message and activity J. Lipid Res., September 1, 2009; 50(9): 1852 - 1862. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Pavoine and F. Pecker Sphingomyelinases: their regulation and roles in cardiovascular pathophysiology Cardiovasc Res, May 1, 2009; 82(2): 175 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. L. Holland and P. E. Scherer PAQRs: A Counteracting Force to Ceramides? Mol. Pharmacol., April 1, 2009; 75(4): 740 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Merrill Jr., T. H. Stokes, A. Momin, H. Park, B. J. Portz, S. Kelly, E. Wang, M. C. Sullards, and M. D. Wang Sphingolipidomics: a valuable tool for understanding the roles of sphingolipids in biology and disease J. Lipid Res., April 1, 2009; 50(Supplement): S97 - S102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Haus, S. R. Kashyap, T. Kasumov, R. Zhang, K. R. Kelly, R. A. DeFronzo, and J. P. Kirwan Plasma Ceramides Are Elevated in Obese Subjects With Type 2 Diabetes and Correlate With the Severity of Insulin Resistance Diabetes, February 1, 2009; 58(2): 337 - 343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Samokhvalov, P. J. Bilan, J. D. Schertzer, C. N. Antonescu, and A. Klip Palmitate- and lipopolysaccharide-activated macrophages evoke contrasting insulin responses in muscle cells Am J Physiol Endocrinol Metab, January 1, 2009; 296(1): E37 - E46. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
